These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 311698)

  • 1. Differential inhibition of adenosine deaminase deficient peripheral blood lymphocytes and lymphoid line cells by deoxyadenosine and adenosine.
    Hirschhorn R; Bajaj S; Borkowsky W; Kowalski A; Hong R; Rubinstein A; Papageorgiou P
    Cell Immunol; 1979 Feb; 42(2):418-23. PubMed ID: 311698
    [No Abstract]   [Full Text] [Related]  

  • 2. Enzyme replacement and other biochemical approaches to the therapy of adenosine deaminase deficiency.
    Polmar SH
    Ciba Found Symp; 1978; (68):213-30. PubMed ID: 227649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A role for purine metabolism in the immune response: Adenosine-deaminase activity and deoxyadenosine catabolism.
    Simmonds HA; Panayi GS; Corrigall V
    Lancet; 1978 Jan; 1(8055):60-3. PubMed ID: 74565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of deoxyadenosine on the activation of ADA inhibited T & B cells.
    Webster AD; Ip H; Pereira S
    Clin Exp Immunol; 1982 Dec; 50(3):587-95. PubMed ID: 6299634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of adenosine on mitogenesis of ADA-deficient lymphocytes.
    Uberti J; Lightbody JJ; Wolf JW; Anderson JA; Reid RH; Johnson RM
    Clin Immunol Immunopathol; 1978 Aug; 10(4):446-58. PubMed ID: 688701
    [No Abstract]   [Full Text] [Related]  

  • 6. Accumulation of deoxyribonucleotides as a possible mediator of immunosuppression in hereditary deficiency of adenosine deaminase.
    Bluestein HG; Willis RC; Thompson LF; Matsumoto S; Seegmiller JE
    Trans Assoc Am Physicians; 1978; 91():394-402. PubMed ID: 314193
    [No Abstract]   [Full Text] [Related]  

  • 7. Establishment and characterization of adenosine deaminase-deficient human T cell lines.
    Kohn DB; Mitsuya H; Ballow M; Selegue JE; Barankiewicz J; Cohen A; Gelfand E; Anderson WF; Blaese RM
    J Immunol; 1989 Jun; 142(11):3971-7. PubMed ID: 2497184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mechanism of inhibition and "reversal" of mitogen-induced lymphocyte activation in a model of adenosine deaminase deficiency.
    Albert D; Bluestein HG; Thompson L; Seegmiller JE
    Cell Immunol; 1984 Jul; 86(2):510-7. PubMed ID: 6610485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S-Adenosylhomocysteine hydrolase activity in a lymphoblastoid cell line from a patient with adenosine deaminase dificiency disease.
    Tsuchiya S; Nakae S; Konno T; Tada K
    J Inherit Metab Dis; 1981; 4(4):197-201. PubMed ID: 6796770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenosine deaminase deficiency and severe combined immunodeficiency disease.
    Thompson LF; Seegmiller JE
    Adv Enzymol Relat Areas Mol Biol; 1980; 51():167-210. PubMed ID: 6255772
    [No Abstract]   [Full Text] [Related]  

  • 11. Rejection of bone marrow transplant and resistance of alloantigen reactive cells to in vivo deoxyadenosine in adenosine deaminase deficiency.
    Cowan MJ; Shannon KM; Wara DW; Ammann AJ
    Clin Immunol Immunopathol; 1988 Nov; 49(2):242-50. PubMed ID: 2971490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deoxyadenosine metabolism and cytotoxicity in cultured mouse T lymphoma cells: a model for immunodeficiency disease.
    Ullman B; Gudas LJ; Cohen A; Martin DW
    Cell; 1978 Jun; 14(2):365-75. PubMed ID: 208780
    [No Abstract]   [Full Text] [Related]  

  • 13. Deoxyribonucleoside toxicity in adenosine deaminase and purine nucleoside phosphorylase deficiency: implications for the development of new immunosuppressive agents.
    Carson DA; Kaye J
    Ciba Found Symp; 1978; (68):115-33. PubMed ID: 115660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of red cell transfusions, thymic hormone and deoxycytidine in severe combined immunodeficiency due to adenosine deaminase deficiency.
    Davies EG; Levinsky RJ; Webster DR; Simmonds HA; Perrett D
    Clin Exp Immunol; 1982 Nov; 50(2):303-10. PubMed ID: 6983936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic basis for immune dysfunction in adenosine deaminase deficiency.
    Carson DA; Iizasa T; Seto S; Carrera CJ; Kubota M; Willis EH; Wasson DB; Kajander O
    Ann N Y Acad Sci; 1985; 451():34-41. PubMed ID: 3878120
    [No Abstract]   [Full Text] [Related]  

  • 16. A phenotypically normal revertant of an adenosine deaminase-deficient lymphoblast cell line.
    Uberti J; Peterson WD; Lightbody JJ; Johnson RM
    J Immunol; 1983 Jun; 130(6):2866-70. PubMed ID: 6854019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin 2 responsive lymphocytes in patients with adenosine deaminase deficiency.
    Cowan MJ; Smith W; Ammann AJ
    Clin Immunol Immunopathol; 1989 Oct; 53(1):59-67. PubMed ID: 2569954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenosine deaminase (ADA) and other enzyme abnormalities in immune deficiency states.
    Goldblum RM; Schmalstieg FC; Nelson JA; Mills GC
    Birth Defects Orig Artic Ser; 1978; 14(6A):73-84. PubMed ID: 215243
    [No Abstract]   [Full Text] [Related]  

  • 19. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s).
    Carson DA; Kaye J; Seegmiller JE
    Proc Natl Acad Sci U S A; 1977 Dec; 74(12):5677-81. PubMed ID: 202960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenosine- and deoxyadenosine-mediated altered pyrimidine metabolism in human adeosine deaminase-deficient lymphoblasts.
    Parker NF; Jack I; Van Der Weyden MB
    J Lab Clin Med; 1982 May; 99(5):731-9. PubMed ID: 6175708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.